Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BID | P55957 | 6/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 5/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | IAPP | P10997 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | F7 | P08709 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11116707 | 0.93 | BID (0.59) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL28219034 | 0.89 | TYR (0.52) | EP300TYRALOX5KDM4EMAPT | |
| SCHEMBL5545182 | 0.88 | IAPP (0.47) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL19465419 | 0.88 | LIPG (0.45) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL30562992 | 0.86 | LIPG (0.44) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL10110677 | 0.83 | TYR (0.54) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL7569666 | 0.81 | TYR (0.57) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL28386803 | 0.81 | TYR (0.57) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL7721087 | 0.81 | TYR (0.57) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL11724971 | 0.81 | TYR (0.57) | BIDMCL1BCL2L1BAK1KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2990873-A1 | PROCESS FOR MAKING LITHOGRAPHIC PRINTING PLATE | Fujifilm Corporation (JP) | 2016-03-02 | — | — | EP | disclosed |
| EP-2557103-B1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | DAINIPPON INK & CHEMICALS (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8519065-B2 | Epoxy compound, curable composition, and cured product thereof | DIC CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20130144030-A1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2557103-A1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | DIC Corporation (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1041526-C | Naphthalene-ring resin, resin composition, and cured product thereof | NIPPON KAYAKU KK (JP) | 1999-01-06 | — | — | CN | disclosed |
| US-5780571-A | RESIN OBTAINED BY CONDENSATION OF NAPHTHOL AND 4,4*-BIS/CHLOROMETHYL/BIPHENYL, OPTIONALLY REACTED WITH EPICHLOROHYDRIN | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0644216-B1 | NAPHTHALENE-RING RESIN, RESIN COMPOSITION, AND CURED PRODUCT THEREOF | NIPPON KAYAKU KK (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0644216-A1 | NAPHTHALENE-RING RESIN, RESIN COMPOSITION, AND CURED PRODUCT THEREOF | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1995-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | BID 4689/4885MCL1 3401/4885BCL2L1 2491/4885 |
| US-20130144030-A1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | HEATR1, EEF1A1, EPN1 | BID 4701/4885MCL1 3532/4885BCL2L1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.